Patent Term Extension Application for EXDENSUR® (depemokimab-ulaa), Patent No. 10,787,509 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-3816

Patent Term Extension Application for EXDENSUR® (depemokimab-ulaa), Patent No. 10,787,509

Documents

Comments

Description

OPEN

Comment Period OpensApr 9, 2026

Type	Title	Posted	Comments	Status
Other	Letter from U. S. Patent and Trademark Office to FDA CDER	Apr 9, 2026	--

CDER

Patent Term Extension Application

Glaxosmithkline

GlaxoSmithKline Intellectual

Property Development Limited

EXDENSUR® (depemokimab-ulaa)

Patent No. 10,787,509

OPEN